CD39 (ENTPD1)

Class

CD39 enzymatic-inhibitory monoclonal antibody

Pathway

Blocks CD39-mediated degradation of extracellular ATP, preserving pro-immune ATP signaling in the immunosuppressive tumor microenvironment

CD39, also called ENTPD1, is an enzyme anchored on the surface of many cell types, including tumor cells, regulatory T cells, and myeloid cells, where it converts extracellular ATP into AMP. This is the first step of a two-enzyme relay, continued by CD73, that ultimately produces adenosine. Extracellular ATP released by stressed or dying cells acts as a danger signal that activates immune cells, while adenosine generally dampens immune activity. Tumors frequently exploit this relay, using high CD39 and CD73 activity to deplete stimulatory ATP and flood the surrounding tissue with suppressive adenosine, helping cancer cells evade immune attack. Inhibiting CD39 interrupts this conversion, preserving ATP-driven immune activation and limiting adenosine formation downstream, with the intent of restoring anti-tumor immune responses within the tumor microenvironment. Because this pathway sits at the intersection of purinergic signaling and immune regulation, CD39 inhibition is studied as one component of a broader adenosine-pathway strategy in oncology, often considered alongside agents targeting CD73 or the adenosine receptor itself. The mechanism is relevant wherever local immune suppression driven by extracellular nucleotide metabolism limits the effectiveness of anti-tumor immune responses.